Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis.

E Alemao; S Johal; Maiwenn Al; Maureen Rutten - van Molken

doi:10.1016/j.jval.2017.05.020

Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis.

E Alemao, S Johal, Maiwenn Al, Maureen Rutten - van Molken

Health Technology Assessment (HTA)

Research output: Contribution to journal › Article › Academic

11 Citations (Scopus)

13 Downloads (Pure)

Original language	English
Pages (from-to)	193-202
Number of pages	10
Journal	Value in Health
Volume	21
Issue number	2
DOIs	https://doi.org/10.1016/j.jval.2017.05.020
Publication status	Published - 2018

Access to Document

10.1016/j.jval.2017.05.020

Repub_116483_O-A.pdfFinal published version, 698 KB

http://hdl.handle.net/1765/116483

Cite this

@article{6f5aa336d7024cbbb919d5c8eb68fca8,

title = "Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis.",

author = "E Alemao and S Johal and Maiwenn Al and {Rutten - van Molken}, Maureen",

year = "2018",

doi = "10.1016/j.jval.2017.05.020",

language = "English",

volume = "21",

pages = "193--202",

journal = "Value in Health",

issn = "1098-3015",

publisher = "Elsevier Ltd.",

number = "2",

}

TY - JOUR

T1 - Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis.

AU - Alemao, E

AU - Johal, S

AU - Al, Maiwenn

AU - Rutten - van Molken, Maureen

PY - 2018

Y1 - 2018

U2 - 10.1016/j.jval.2017.05.020

DO - 10.1016/j.jval.2017.05.020

M3 - Article

SN - 1098-3015

VL - 21

SP - 193

EP - 202

JO - Value in Health

JF - Value in Health

IS - 2

ER -